menu ☰
menu ˟

[Comment] KEYNOTE-006: a success in melanoma, but a long way to go

16 Aug 2017

A breakthrough in cancer therapy was achieved by the introduction of immune checkpoint inhibition, starting with the US Food and Drug Administration approval of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)-specific antibody ipilimumab in 2011.1,2 Since then, clinical experience indicates that only around 20% of patients with late-stage melanoma experience durable responses with ipilimumab, but can pay a high price in terms of adverse events, because ipilimumab has been associated with autoimmune reactions like colitis that can require treatment discontinuation.

Click here to view the full article which appeared in The Lancet

IPH Logo